Non Hodgkin Lymphoma Clinical Trial
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
Summary
The primary objective of this study is to determine if axicabtagene ciloleucel is superior to standard of care therapy (SOCT), as measured by progression-free survival (PFS) in participants with relapsed/refractory follicular lymphoma.
Full Description
Five years after the last study participant is randomized, participants who have received axicabtagene ciloleucel will transition to a separate Long-term Follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up assessments.
Eligibility Criteria
Key Inclusion Criteria:
Histologically-confirmed follicular lymphoma (FL) (Grade 1, 2, or 3a)
Relapsed/refractory (R/r) disease after first-line chemoimmunotherapy and high-risk disease with relapse or progression within 24 months of the initial course of chemoimmunotherapy (ie, POD24), Or r/r disease after ≥ 2 prior systemic lines of therapy
Clinical indication for treatment.
At least 1 measurable lesion per the Lugano Classification {Cheson 2014}
Adequate renal, hepatic, pulmonary, and cardiac function
Exclusion Criteria:
Transformed FL
FL Grade 3b
Prior CD19-targeted therapy
Prior CAR therapy or other genetically modified T-cell therapy
Uncontrolled fungal, bacterial, viral, or other infection
Active Infection with human immunodeficiency virus, hepatitis B virus or hepatitis C virus
History or presence of a central nervous system (CNS) disorder.
History of autoimmune disease
Known history or CNS lymphoma involvement
Cardiac lymphoma involvement
History of clinically significant cardiac disease within 6 months of randomization
Neuropathy greater than Grade 1
Females who are pregnant or breastfeeding
Individuals of both genders who are not willing to practice birth control
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
Orange California, 92868, United States
Stanford California, 94305, United States
Denver Colorado, 80218, United States
Washington District of Columbia, 20007, United States
Westwood Kansas, 66205, United States
Boston Massachusetts, 02215, United States
Hackensack New Jersey, 07601, United States
New York New York, 10032, United States
Pittsburgh Pennsylvania, 15232, United States
Sioux Falls South Dakota, 57105, United States
Nashville Tennessee, 37203, United States
Nashville Tennessee, 37232, United States
Houston Texas, 77030, United States
Richmond Virginia, 23298, United States
Lille cedex , 59037, France
Montpellier , 34295, France
Rozzano , 20089, Italy
How clear is this clinincal trial information?